What is Medherant?
Medherant is at the forefront of developing advanced, sustainable transdermal drug delivery patches designed to improve patient care across women's health, pain management, and central nervous system (CNS) diseases. Leveraging its proprietary TEPI Patch technology, the company aims to deliver enhanced convenience, confidence, and comfort to patients. Medherant actively seeks strategic partnerships to advance the development of transdermal and topical delivery solutions utilizing its cutting-edge platform.
How much funding has Medherant raised?
Medherant has raised a total of $17.7M across 6 funding rounds:
Angel/Seed
$1.9M
Multiple Rounds
$9.5M
Corporate Investment
$2.5M
Other Financing Round
$3.8M
Angel/Seed (2016): $1.9M with participation from Mercia Technologies
Series A (2017): $2M led by Mercia Technologies PLC.
Private Equity (2017): $4.8M supported by Mercia Technologies PLC
Angel/Seed (2017): $2.7M featuring Mercia Fund Management and Mercia Technologies PLC.
Corporate Investment (2019): $2.5M backed by Mercia Technologies
Other Financing Round (2023): $3.8M, investors not publicly disclosed
Key Investors in Medherant
Mercia Technologies PLC
Mercia Technologies PLC is a UK-based investment firm specializing in providing equity and debt financing to businesses with growth ambitions. They act as investment partners from scale-up to exit, offering venture capital and private equity to accelerate growth.
Mercia Fund Management
Mercia Fund Management Ltd operates within the Venture Capital & Private Equity sector, providing capital to UK businesses. They are known for supporting companies with growth potential from their base in the United Kingdom.
What's next for Medherant?
The recent major strategic investment positions Medherant for accelerated growth and market penetration. This capital infusion is expected to fuel further research and development, scale manufacturing capabilities, and expand commercialization efforts for its innovative transdermal patches. The company's focus on key therapeutic areas and its advanced TEPI Patch technology suggest a trajectory towards becoming a leader in the pharmaceutical delivery sector, with potential for further strategic alliances and funding rounds as it advances its product pipeline.
See full Medherant company page
